Mutations within ASXL1 are found in 8% of MPN, 11% of MDS, 43% of chronic myelomonocytic leukemia, 7% of de novo AML, and 47% of secondary AML [35]. Here, ASXL1 is linked to myeloproliferative neoplasm.